Furthermore, the restoration of hsa-miR-375 levels might represent a therapeutic approach to mitigate these effects by repressing CLDN1 expression, potentially inhibiting tumor progression and improving patient outcomes. This evidence concerns the gene CLDN1 and neoplasm.